title: [Effect of anti-Helicobacter pylori on the prognosis  in patients with acute cerebral infarction].
abstract: OBJECTIVE
  To investigate the effect of anti-Helicobacter pylori on the inflammation mediators and prognosis in patients with acute cerebral infarction.
  
  
  METHODS
  Routine urease test was carried out in patients with acute cerebral infarction in our hospital. The acute cerebral infarction patients with positive urease test were randomly divided into a treatment group (conventional therapy+anti-Helicobacter pylori therapy) and a control group (conventional therapy). C-reactive protein, triglycerides, and fibrinogen changes were examined before and after the treatment, symptoms of acute cerebral infarction conditions were observed,and 6-months and 1- year cerebral infarction readmission rates were measured in the 2 groups.
  
  
  RESULTS
  Compared with before the treatment,the C-reactive protein, triglycerides, and plasma fibrinogen decreased significantly in the treatment group, while there was no significant change in the control group. The 6-months and 1-year cerebral infarction readmission rates were significantly lower than those in the control group.
  
  
  CONCLUSIONS
  H. pylori infection may be a risk factor for cerebral infarction. A positive anti-Helicobacter pylori infection treatment can significantly improve the efficiency of cerebral infarction and reduce the short-term readmission rate.
authors.affiliation: Department of Internal Medicine, Third People's Hospital of Yuyao,Yuyao Zhejiang, China. 635450525@qq.com
authors.forename: Guiqun
authors.initials: G
authors.lastname: Pan
mesh_terms: D000368:Aged; D000658:Amoxicillin / Q000008:administration & dosage; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D002097:C-Reactive Protein / Q000032:analysis; D002544:Cerebral Infarction / Q000188:drug therapy* / Q000382:microbiology*; D005260:Female; D005340:Fibrinogen / Q000032:analysis; D016481:Helicobacter Infections / Q000150:complications / Q000188:drug therapy*; D016480:Helicobacter pylori; D006801:Humans; D008297:Male; D008875:Middle Aged; D009853:Omeprazole / Q000008:administration & dosage; D011379:Prognosis; D012307:Risk Factors; D014280:Triglycerides / Q000097:blood
chemical_list: D000900:Anti-Bacterial Agents; D014280:Triglycerides; D000658:Amoxicillin; D005340:Fibrinogen; D002097:C-Reactive Protein; D009853:Omeprazole